{"filings":[{"id":1111002,"accession_number":"0001193125-26-274137","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K/A","filed_at":"2026-06-17T20:05:13+00:00","items":["5.02"],"status":"ready","headline":"Biote Corp. sets interim CEO Robert Peterson's comp: $658,800 base, equity, severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Annual base salary of $658,800; eligible for incentive up to 72.5% of base salary.","Stock option award for 0.56% of outstanding shares; additional option if appointed permanent CEO.","Severance: 12-month base salary, COBRA reimbursement on termination without cause or for good reason.","Change-in-control severance includes acceleration of unvested time-based equity awards.","Appointment effective June 8, 2026; board approved comp agreement on June 12, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":808476,"accession_number":"0001193125-26-253858","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2026-06-02T21:17:02+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Biote CEO Christensen resigns; CFO Peterson named Interim CEO; Marc Beer Executive Chairman; FY2026 guidance reaffirmed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bret Christensen resigns as CEO effective June 8, 2026 for personal/family reasons; remains a Class III director.","CFO and Chief Business Officer Bob Peterson appointed Interim CEO and director; search for permanent CFO initiated.","Chairman Marc Beer becomes Executive Chairman with base salary of $521,200, bonus up to 85%, and option for 114,157 shares.","Company reaffirms FY2026 guidance: revenue above $190M, Adjusted EBITDA above $38M; expects procedure revenue growth in H2.","Separation agreement for Christensen includes 3-month option exercise period and 130,000-share stock option grant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":500079,"accession_number":"0001193125-26-229013","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2026-05-18T20:30:20+00:00","items":["5.07"],"status":"ready","headline":"biote Corp. 2026 annual meeting elects directors, ratifies Deloitte as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Andrew R. Heyer elected Class I director with 22,759,692 for, 3,960,800 withheld; 2,861,704 broker non-votes.","Dana Jacoby elected Class I director with 23,020,635 for, 3,699,857 withheld; 2,861,704 broker non-votes.","Stockholders ratified Deloitte & Touche as auditor for FY2026: 29,507,419 for, 67,387 against, 7,390 abstain.","Annual meeting held May 12, 2026; described in proxy statement filed April 2, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95763,"accession_number":"0001193125-26-208965","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biote Q1 revenue $44.9M (-8.3% YoY); net income $2.7M vs $15.8M, hit by hormone pellet recall","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $44.9M, down 8.3% YoY; net income $2.7M ($0.06 EPS) vs $15.8M ($0.37) in Q1 2025.","Procedure revenue fell 13.2% to $31.3M due to voluntary recall of Asteria Health hormone pellets; supplements up 19.1% to $11.0M.","Gross margin 68.9% vs 74.3% from higher replacement costs and reduced manufacturing efficiency at Asteria.","Adjusted EBITDA $8.7M (19.4% margin); sales team expansion nearing target of 120 representatives.","Management expects return to procedure growth in second half of 2026 after recall impact."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":44935000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95762,"accession_number":"0001193125-26-142147","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"biote Corp. posts April 2026 investor presentation on its website","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated April 2026 available at ir.biote.com/news-events/presentations.","No financial results, guidance changes, or material events disclosed in the 8-K.","Presentation titled 'Transforming Healthy Aging' contains strategic updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109058,"accession_number":"0001193125-26-102129","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biote Q4 revenue $46.4M; net income $2.6M; anticipates procedure growth H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $46.4M, gross margin 68.0%; net income $2.6M ($0.06 diluted EPS), down from $3.5M ($0.10) in Q4 2024.","Full year 2025 revenue $192.2M; net income $31.6M ($0.74 diluted EPS), versus $0.05M ($0.09) in 2024.","Adjusted EBITDA Q4 $11.7M (25.2% margin); full year adjusted EBITDA $53.5M (27.8% margin).","CEO Bret Christensen anticipates return to procedure revenue growth in second half of 2026.","Company rebuilding commercial sales coverage; commercial transition impacted 2025 results as expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109057,"accession_number":"0001193125-26-022818","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Biote subsidiary recalls hormone pellets due to metal particulate; expects $1.3M Q4 charge","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Asteria Health voluntarily recalled specific lots of hormone pellets shipped May 20, 2025–Jan 19, 2026 due to potential metal particulate.","Expects ~$1.3M one-time charge in Q4 2025 cost of products for write-off of impacted inventory.","Additional recall costs in 2026 estimated at ~$1.0M; recall conducted with FDA knowledge.","Company states recall does not materially impact ability to supply practitioners or service patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125525,"accession_number":"0001193125-25-266910","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biote Q3 2025: Revenue $48.0M, net income $9.2M ($0.22 EPS), down YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $48.0M, gross profit margin 71.8%.","Net income $9.2M ($0.22 diluted EPS) vs $12.7M ($0.33) in Q3 2024.","Adjusted EBITDA $12.9M (26.9% margin).","Repurchased ~1 million shares of Class A common stock during Q3.","Reiterated 2025 financial guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":145811000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142261,"accession_number":"0000950170-25-104014","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biote Q2 rev $48.9M, net income $3.9M vs year-ago loss; Adj. EBITDA up 19%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $48.9M, gross margin 71.6%; net income $3.9M ($0.10 diluted EPS) vs net loss $10.4M ($0.21 loss) in Q2 2024.","Adjusted EBITDA $15.2M (margin 31.1%), up 19.1% YoY; benefit from Q3 shift of annual marketing event and 503B vertical integration.","CEO announced organizational restructuring in early May to accelerate new provider and clinic growth; new leadership and upgraded sales compensation.","Q2 revenue decreased slightly YoY, but profitability and margins expanded significantly."],"consensus_eps_estimate":null,"consensus_eps_actual":0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":97855000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160272,"accession_number":"0001193125-25-137873","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"biote Corp appoints Rich Barrera to Board, filling Heyer vacancy","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard R. Barrera appointed as Class II director effective June 5, 2025; term expires at 2027 annual meeting.","Barrera is Founder & CEO of Roystone Capital, a top institutional shareholder; considered independent.","Appointed to Nominating and Corporate Governance Committee; eligible for non-employee director compensation.","Initial equity award of $337,500 in stock options vesting over 3 years; annual cash retainer of $50,000.","Barrera replaces Steven J. Heyer, who resigned; has 20+ years investment experience and an MBA from Harvard."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160271,"accession_number":"0001193125-25-135341","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Steven J. Heyer resigns from biote Corp board effective June 2, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven J. Heyer resigned from the board of directors effective June 2, 2025.","Resignation was not due to any disagreement with the company on operations, policies, or practices.","Board has not yet selected a replacement for the vacancy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160270,"accession_number":"0001193125-25-119861","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"biote Corp. announces 2025 annual meeting voting results; directors elected, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Marc D. Beer elected as Class III director with 34,765,989 votes for, 4,983,029 withheld (2,584,180 broker non-votes).","Bret Christensen elected as Class III director with 38,942,124 votes for, 806,894 withheld (2,584,180 broker non-votes).","Ratification of Deloitte & Touche as auditor for FY 2025: 42,246,818 for, 86,326 against, 54 abstain, no broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160269,"accession_number":"0000950170-25-065638","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"Biote Q1 net income $15.8M vs loss, revenue $49.0M, restructuring 16 employees","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $15.8M ($0.37 diluted EPS) vs net loss of $(5.7M) ($(0.12) per share) in Q1 2024.","Revenue $49.0M, up 4.7% YoY; dietary supplements +25.5%, procedure revenue -3.6%.","Adjusted EBITDA $13.8M (28.1% margin); gross profit margin 74.3% from vertical integration.","Board authorized restructuring on May 1, cutting 16 employees; completed May 5; charges $0.6-0.8M.","Company maintains 2025 financial outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":48992000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160268,"accession_number":"0001193125-25-093531","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"biote Corp. Executive Chairman Marc Beer transitions to part-time, salary reduced to $196K","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective April 1, 2025, Marc Beer moved from full-time to part-time Executive Chairman.","Annual base salary reduced from $490,000 to $196,000 retroactively effective April 1.","Beer expected to become Non-Executive Chairman by end of Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178568,"accession_number":"0001193125-25-055224","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"biote Corp. posts March 2025 investor presentation; no specific financial guidance disclosed in excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company filed Form 8-K announcing availability of updated Investor Presentation on its website.","Presentation is dated March 2025 and accessible at ir.biote.com under Presentations.","No specific financial metrics, guidance changes, or material events were included in the filing text.","Exhibit 99.1 only contains title slides; full presentation content not provided in the filing excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178567,"accession_number":"0001193125-25-052946","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"biote Q4 2024 revenue up 9% to $49.8M; EPS falls to $0.10 from $0.18","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Q4 2024 revenue $49.8M, procedure revenue $36.6M, net income $3.5M ($0.10 EPS) vs $12.1M ($0.18 EPS) a year ago.","Full year 2024 revenue $197.2M (+6.4% YoY); net income $0.05M (vs net loss $2.8M in 2023).","Adjusted EBITDA Q4 $15.1M (30.3% margin); full year $58.2M (29.5% margin).","Gross profit margin improved to 71.8% Q4 (70.5% full year) on vertical integration of 503B facility.","Cash and cash equivalents $39.3M at year-end; fiscal 2025 outlook provided but not detailed in excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178566,"accession_number":"0001193125-25-017314","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"CEO Terry Weber retires; Bret Christensen named new CEO effective Feb 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Terry Weber resigns as CEO and director, effective Feb 1, 2025; becomes Strategic Advisor.","Bret Christensen named CEO and director; formerly CEO of DermTech and CCO at Insulet.","Christensen receives $700k base salary, up to 85% bonus, 1.5M share option grant, $200k relocation.","Weber receives $621,700 severance and $20k/month consulting fee through Feb 2026.","Weber's equity awards continue vesting through later of consulting term end or Feb 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195231,"accession_number":"0001193125-24-255973","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biote Q3 revenue $51.4M (+12.8% YoY); EPS $0.33; Adj. EBITDA $16.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $51.4M, up 12.8% YoY; procedure revenue $37.9M.","Gross profit margin 70.5%, up from 64.5% a year ago on vertical integration savings.","Net income $12.7M ($0.33 diluted EPS) vs. $19.6M ($0.24) in Q3 2023.","Adjusted EBITDA $16.2M, margin 31.5%; grew 15.4% YoY.","Launched proprietary clinical decision support software in September 2024 to strengthen competitive position."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":147357000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211487,"accession_number":"0001193125-24-196974","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biote Q2 revenue $49.2M, net loss narrows to $10.5M; procedure revenue grows 7.8% sequentially","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $49.2M; procedure revenue $38.4M, up 7.8% QoQ vs 6.6% in Q1.","Net loss of $(10.5)M (EPS $(0.19)) improved from $(13.1)M ($(0.25)) in Q2 2023.","Adjusted EBITDA of $12.7M; gross profit margin 68.9% with $1.2M inventory step-up from Asteria Health acquisition.","New clinics grew ~30% in H1 2024; 2024 full-year financial guidance reaffirmed.","BioteRx roll-out on track; management plans further geographic and therapeutic wellness expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":95973000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211486,"accession_number":"0001193125-24-175600","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2024-07-05T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"biote settles stockholder litigation with $60M share repurchase agreement","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Repurchased ~4.1M Paired Interests for $30M on June 28, 2024.","Additional $10M repurchases at 12, 24, and 36-month anniversaries, totaling $60M.","Released and canceled ~4.0M earnout Paired Interests for no additional consideration.","Mutual release of all claims in Donovitz litigation and entry into voting agreement.","Settlement supersedes previously disclosed binding term sheet from June 14, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211485,"accession_number":"0001193125-24-175041","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"biote Corp. terminates Mary Puncochar, Head of Strategic Sales & Business Analytics","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mary Puncochar terminated other than for cause; severance includes ~$202,781 base salary (9 months).","Also receives prorated target bonus of $54,075 and reimbursement for medical/dental/vision for 9 months.","Separation agreement includes customary release of all claims against the Company.","No replacement announced; Puncochar had served as Head of Strategic Sales since March 2024, prior CCO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230149,"accession_number":"0001193125-24-164885","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Biote settles stockholder litigation with $60M share repurchase and earnout cancellation","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Repurchases ~8.3M shares from Marci Donovitz for $60M ($7.23 avg) over 3 years.","Cancels ~4.0M earnout shares owned by Donovitz for no additional consideration.","Combined with prior Dr. Gary Donovitz deal, total 26.7M shares repurchased and 8.0M earnout shares cancelled.","First tranche: ~4.1M shares for $30M due by June 28, 2024.","Mutual release of all litigation claims; parties to negotiate a voting agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230148,"accession_number":"0001193125-24-146528","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"biote Corp. stockholders elect three Class II directors, ratify Deloitte & Touche as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders elected Steven J. Heyer, S. Mark Cone, and Debra L. Morris as Class II directors for terms expiring 2027.","Heyer received 39,570,108 for and 6,471,544 withheld; Cone 41,383,463 for, 4,742,536 withheld; Morris 40,009,750 for, 6,116,249 withheld.","Broker non-votes were 5,285,359 on Heyer and 5,201,012 on Cone and Morris.","Ratification of Deloitte & Touche LLP as independent auditor for FY2024 passed with 47,312,863 for, 3,771,943 against, and 242,205 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230147,"accession_number":"0001193125-24-133133","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biote reports Q1 revenue $46.8M (+4.4%), net loss narrows to $5.8M; reaffirms 2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $46.8M (+4.4% YoY); procedure revenue $37.4M (+6.6%).","Net loss $(5.8)M vs $(21.4)M prior year; EPS $(0.06) vs $(0.39).","Adjusted EBITDA $14.2M (+8.0%); margin 30.2% (+100bps).","Gross margin 71.4% (+240bps) on improved mix.","BioteRx launch progressing; reaffirms FY2024 guidance with H2 acceleration."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":46804000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230146,"accession_number":"0001193125-24-122394","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Biote settles founder litigation, repurchases all 18.4M shares for ~$76.9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repurchases 18.4M shares at $4.17 avg price; $32.2M paid on April 26, remainder over 3 years.","Mutual release of all claims in the Donovitz litigation; founder advisory agreement terminated.","Two-year non-compete and non-solicitation agreements with Donovitz; voting agreement signed.","CEO says settlement resolves costly litigation and multi-year repurchase will be accretive.","Financial impacts of settlement to be detailed in Q1 results on May 7, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248585,"accession_number":"0001193125-24-067887","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"biote Corp. posts March 2024 investor presentation; no material new details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor presentation dated March 2024 posted on company website.","Presentation contains general business overview and forward-looking statements.","No specific financial updates, guidance changes, or new data were included.","Presentation is available at the Investor Relations section of biote's website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248584,"accession_number":"0001193125-24-065961","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biote Q4 revenue $45.7M (+2.7% YoY), net income $12.1M; FY adj. EBITDA $55.3M (+10.2%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 procedure revenue $34.9M (+6.6%); gross margin 69.4% (up >400 bps); diluted EPS $0.18.","Full-year revenue $185.4M (+12.4%); net loss $2.8M; adj. diluted EPS $0.13.","Practitioner network grew to 7,100 from 6,400; launched BioteRx hormone/wellness line.","Agreed to repurchase 18.4M founders' shares plus separate $20M buyback program.","Reaffirmed 2024 guidance with expectation of accelerated growth in H2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248583,"accession_number":"0001193125-24-040005","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Biote settles founder litigation, to repurchase 18.4M shares for $76.9M at $4.17 each","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Repurchases 5.1M Class A shares and 13.3M Paired Interests from founder Donovitz for $76.9M total.","Average price $4.17 per share; payments spread over three years: $32.2M now, $15.1M, $19.1M, $10.5M.","Mutual release of all claims; founder advisory agreement terminated, two-year non-compete agreed.","Existing $20M share repurchase authorization remains separate and unchanged.","CEO says resolution ends costly litigation and the buyback is accretive to shareholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248582,"accession_number":"0001193125-24-015456","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2024-01-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biote announces $20M share repurchase authorization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Jan 25, 2024, board approved first-ever $20M share repurchase program for Class A common stock.","Repurchases may occur in open market, privately negotiated transactions, or via other means.","CEO cites strong balance sheet and confidence in growth opportunity as rationale for buyback.","Program may be modified, suspended, or discontinued at any time; no obligation to repurchase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248581,"accession_number":"0001193125-24-009293","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2024-01-17T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Biote lowers FY2023 revenue guidance to $185-187M; acquires Asteria Health for $8.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 revenue expected $185-187M (prior guidance $190-200M lower end); Adjusted EBITDA $54-56M (prior $56-60M).","Q4 2023 revenue $45-47M; Adj. EBITDA $12-14M; nutraceutical revenue down ~15% due to distributor exit.","FY2024 guidance: revenue >$200M, Adj. EBITDA >$60M; first half growth low-single digits, improving in H2.","Acquired Asteria Health (503B manufacturer) for $8.5M cash + up to $0.5M earnout; close expected Q1 2024.","Acquisition enables vertical integration of hormone product manufacturing and margin improvement."],"consensus_eps_estimate":null,"consensus_eps_actual":0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":185360000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248580,"accession_number":"0001193125-24-006634","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2024-01-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"biote Corp appoints Robert Peterson as CFO, succeeding Samar Kamdar","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Peterson named CFO effective Jan 8, 2024; base salary $425,000 plus bonus and equity awards.","Samar Kamdar transitions out as CFO, to remain through Feb 29, 2024 as advisor; transition unrelated to financial results.","Peterson previously CFO of Virbac Corp; brings 15 years health/wellness and public company experience.","Peterson receives initial RSUs valued at $177,000 and 400,000 stock options under 2022 Equity Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266079,"accession_number":"0001193125-23-272557","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biote Q3 revenue $45.6M (+8.5% YoY); net income $19.6M; Adj. EBITDA $14.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $45.6M (+8.5% YoY) driven by procedure revenue growth of 7.4% and supplement growth of 5.1%.","Net income $19.6M (43.1% margin) vs $0.5M in prior year; basic EPS $0.25 vs $0.00.","Adjusted EBITDA $14.0M (+14.7% YoY); margin 30.8% (+165bps).","Reiterated FY2023 guidance: revenue $190-200M, Adj. EBITDA $56-60M; expects lower end.","Progress in commercial trials of complementary wellness therapeutics (sexual health, weight loss, preventive)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":139657000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283312,"accession_number":"0001193125-23-209103","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biote Q2 revenue up 19% to $49.3M; FY2023 guidance narrowed to lower end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $49.3M (+19.1% YoY) driven by procedure (+9.8%) and supplement (+52.8%) growth; gross margin 67.9% (+60 bps).","GAAP net loss $(13.1M) ($(0.25)/share) vs $(21.3M) ($(0.34)) prior year; adjusted EBITDA $14.5M (+10.6%).","FY2023 guidance lowered to lower end of range: revenue $190-200M, adjusted EBITDA $56-60M, citing moderate H2 pace.","Completed warrant exchange and secondary offering to enhance share liquidity; launched Men's Health division and trials for expanded wellness products."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":94100000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302755,"accession_number":"0001193125-23-163673","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["1.01","3.03","5.07","8.01","9.01"],"status":"ready","headline":"Biote completes warrant exchange; 97.5% of public warrants tendered, warrant amendment enacted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["8,191,336 public warrants (97.5%) and 4,464,900 private warrants (87.4%) validly tendered in exchange offer.","Each warrant exchanged for 0.23 shares of common stock; settlement expected by June 9, 2023.","Company entered warrant amendment allowing forced conversion of remaining warrants at 0.207 shares per warrant.","Over 50% consent threshold met for amendment; company will exchange all remaining outstanding warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302754,"accession_number":"0001193125-23-162650","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2023-06-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"biote Corp. selling stockholder sells 5.2M shares at $5.35 in underwritten secondary offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Selling stockholder offered 5,217,392 shares of Class A common stock at $5.35 per share; underwriter partially exercised option for additional 576,108 shares.","Offering closed June 7, 2023; underwriter Roth Capital Partners; shares registered on effective S-1.","Company does not receive any proceeds; all shares sold by selling stockholder.","Underwriting agreement includes customary representations, indemnification, and termination provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302753,"accession_number":"0001193125-23-149442","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"biote shareholders reject ratification of Deloitte & Touche as auditor at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders voted 19,843,341 for, 21,464,530 against ratification of Deloitte & Touche as auditor for FY2023.","Ratification proposal failed; board said it will consider shareholder views for future auditor appointments.","Directors Andrew R. Heyer and Dana Jacoby elected as Class I directors with 18.0M and 18.2M votes for, respectively."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.15,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302752,"accession_number":"0001193125-23-139561","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Biote Q1 revenue $44.8M (+20.7%), net loss $21.4M; launches warrant exchange offer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $44.8M (+20.7% YoY); gross margin 69.1% (+220 bps).","Net loss $(21.4)M ($(0.39) per share) vs net income $9.4M in Q1 2022.","Adjusted EBITDA $13.1M (+12.4% YoY); maintains FY 2023 guidance $190-200M revenue, $56-60M adj EBITDA.","Offer: each outstanding warrant exchanged for 0.23 common shares; consent to convert remaining at 0.207.","Parties representing 19.4% of public warrants and 59.3% of private warrants have agreed to tender."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":44843000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322384,"accession_number":"0001193125-23-082331","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biote reports record FY2022 revenue $165M, Q4 adj EBITDA up 40%; guides FY2023 rev $190-200M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $44.5M (+18.5%), net income $12.8M, diluted EPS $0.18; adjusted EBITDA $13.1M (+40%).","FY2022 revenue $165.0M (+18.3%), net income $1.3M, diluted EPS loss ($0.12); adjusted EBITDA $50.1M (+24.6%).","2023 guidance: revenue $190-200M, adjusted EBITDA $56-60M; expects stronger H2 performance.","Completed secondary offering in Jan 2023 to increase trading liquidity and broaden institutional ownership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322383,"accession_number":"0001193125-23-079227","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2023-03-24T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"biote Corp. restating 2022 Q2/Q3 results; earnout liability error, EPS revision","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee determined Q2 and Q3 2022 unaudited financials should no longer be relied upon due to earnout valuation error.","Error overstated earnout liability and gain/loss from change in fair value; restatement to reduce both.","Changes in fair value of warrant and earnout liabilities will be attributed to operating subsidiary Holdings, not parent.","Restatement will reduce basic and diluted earnings per share; no impact on revenue, operating income, or cash flows.","Company does not believe the error stems from a material weakness in internal controls."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322382,"accession_number":"0001193125-23-044861","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2023-02-22T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Biote Corp. finalizes 2022 executive bonuses and adopts amended bylaws","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Teresa Weber received $3.15M non-equity incentive plan compensation; total 2022 comp $6.69M.","CFO Samar Kamdar awarded $45,267 bonus; total 2022 comp $763,309.","VP Mary Elizabeth Conlon received $111,397 bonus; total 2022 comp $766,797.","Board adopted amended bylaws effective Feb 21, 2023, updating stockholder nomination and proposal procedures.","Bylaw changes include Rule 14a-19 compliance requirements and updated Delaware law provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340429,"accession_number":"0001193125-22-280186","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biote Q3 revenue $42M (+18% YoY); expects upper end of 2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $42.0M, up 18% YoY; net loss $(6.3)M, GAAP diluted EPS $(1.74) due to transaction costs.","Adjusted EBITDA $12.2M (+19% YoY); expects upper end of 2022 revenue $160-$166M and adj. EBITDA $47-$51M.","Gross margin improved to 68.2% from 65.4% on favorable product mix.","Operating income $7.8M, down 13% due to $3.1M transaction and legal costs.","Cash from operations $6.4M in Q3; sales force expansion on track."],"consensus_eps_estimate":null,"consensus_eps_actual":0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":120472000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340428,"accession_number":"0001193125-22-278621","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Biote appoints former Apria CFO Debra L. Morris to Board, increasing size to seven","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from six to seven members; Debra L. Morris appointed effective November 3, 2022.","Ms. Morris previously served as EVP and CFO of Apria, Inc. from March 2013 to October 2022.","She will receive annual cash retainers of $45,000 (board) and $10,000 (audit committee), plus initial equity award of $350,000 (options vesting over 36 months).","She is deemed independent under Nasdaq rules.","Appointment includes standard indemnification agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340427,"accession_number":"0001193125-22-260091","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2022-10-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"biote Corp. releases updated October 2022 corporate presentation","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Company released an updated Investor Presentation dated October 2022, available on its website.","No financial results or forward-looking guidance were included in the release.","Presentation is accessible at https://ir.biote.com/news-events/presentations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357704,"accession_number":"0001193125-22-230045","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2022-08-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biote wins Nasdaq relisting approval; trading resumes Aug 29 under BTMD and BTMDW","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Application to relist on the Nasdaq Global Market approved; effective at market open on August 29, 2022.","Class A common stock and warrants will resume trading under existing symbols BTMD and BTMDW.","Relisting from OTC Pink to Nasdaq is expected to enhance liquidity and market visibility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357703,"accession_number":"0001193125-22-228169","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2022-08-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Biote appoints Samar Kamdar as CFO; Robbin Gibbins to transition out by Nov 15","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Samar Kamdar named CFO effective Aug 24, 2022; reports to CEO Terry Weber.","Kamdar receives $350K base salary, 40% annual bonus, and 250K stock option grant.","Outgoing CFO Robbin Gibbins will remain through Nov 15, 2022, to assist transition.","Kamdar previously served as CFO of Slync.io and TaxAct; holds BSEE and MBA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357698,"accession_number":"0001193125-22-221331","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K/A","filed_at":"2022-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biote corrects Q2 2022 net income down $9.4M; operating loss widened by $9.4M on omitted deal costs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corrected Q2 2022 net income $40.3M (was $49.7M); operating loss $(85.6M) (was $(76.2M)).","Six-month net income now $49.7M (was $59.1M); operating loss $(75.8M) (was $(66.4M)).","Omitted $7.2M in excess fair value of shares and $2.2M consulting costs related to May 2022 business combination.","Revenue of $47.5M and adjusted EBITDA of $13.1M for Q2 2022 were not impacted.","Full-year 2022 guidance for revenue and adjusted EBITDA remains unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357702,"accession_number":"0001193125-22-216343","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biote Q2 revenue up 19% to $41.4M; raises adjusted EBITDA guidance to $47-51M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $41.4M (+19% YoY); net income $49.7M (includes $79M stock comp and $123M earnout adjustment).","Adjusted EBITDA $13.1M (+21% YoY); cash $82.7M at quarter end.","Raises FY2022 adjusted EBITDA guidance to $47-51M; maintains revenue guidance of $160-166M.","CEO cites no direct impact from macro factors; sales force and geographic expansion on track."],"consensus_eps_estimate":null,"consensus_eps_actual":2.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":78502000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357701,"accession_number":"0001193125-22-204281","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2022-07-28T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"biote Corp. enters Standby Equity Purchase Agreement for up to 5M shares with Yorkville","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Agreement with YA II PN, Ltd. (Yorkville) allows biote to sell up to 5,000,000 shares of Class A common stock over 36 months.","Purchase price set at 97% of lowest daily VWAP during a three-day pricing period.","As consideration, biote issued 25,000 Commitment Shares upon execution.","Yorkville's purchase obligation subject to conditions including effective registration statement; shares exempt from registration under Section 4(a)(2).","Ownership limitation caps Yorkville's beneficial ownership at 4.99% of outstanding common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357700,"accession_number":"0001193125-22-196992","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2022-07-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"biote Corp. amends Investor Rights Agreement, waives lock-up on 3.28M shares to meet Nasdaq float requirements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company entered Amended and Restated Investor Rights Agreement allowing it to waive lock-up restrictions at its sole discretion.","Lock-ups waived on 3,277,720 Shares to comply with Nasdaq initial listing public float requirement.","Additional lock-up waivers possible if deemed in best interests of stockholders (e.g., for capital raising or strategic use).","Agreement amends and restates the prior Investor Rights Agreement dated May 26, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357699,"accession_number":"0001193125-22-196756","cik":1819253,"company_name":"biote Corp.","ticker":"BTMD","form_type":"8-K","filed_at":"2022-07-19T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq Panel to delist biote Corp. on July 20; company plans appeal and OTC Pink Market trading","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Panel determined to delist BTMD Class A common stock and warrants for non-compliance with Round Lot Holder and Market Value of Unrestricted Publicly Held Shares requirements.","Trading suspended effective July 20, 2022; company expects to trade on OTC Pink Market pending appeal.","Company believes it will meet both listing requirements by July 19 and intends to appeal to Nasdaq Listing and Hearing Review Council."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":75350517.52749999,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-07-19T23:59:59+00:00|357699"}